✦ LIBER ✦

GW9662, a potent antagonist of PPARγ, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARγ agonist rosiglitazone, independently of PPARγ activation

✍ Scribed by Jill M Seargent; Elisabeth A Yates; Jason H Gill

Book ID: 110008490
Publisher: Nature Publishing Group
Year: 2004
Tongue: English
Weight: 174 KB
Volume: 143
Category: Article
ISSN: 0007-1188
DOI: 10.1038/sj.bjp.0705973

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of rosiglitazone, a PPAR-γ agoni

Effects of rosiglitazone, a PPAR-γ agonist, on the contractility of bovine uterus in vitro

✍ A. RIZZO; M. SPEDICATO; C. COSOLA; G. MINOIA; M. T. ROSCINO; S. PUNZI; R. L. SCI 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 143 KB

PPAR-γ agonist inhibits Ang II-induced a

PPAR-γ agonist inhibits Ang II-induced activation of dendritic cells via the MAPK and NF-κB pathways

✍ Wei-guo, Zhu; Hui, Yan; Shan, Li; Yun, Zhang; Wen-cheng, Nie; Fu-lin, Yu; Fang-y 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 607 KB

Compound 48, a novel dual PPAR α/γ ligan

Compound 48, a novel dual PPAR α/γ ligand, inhibits the growth of human CML cell lines and enhances the anticancer-effects of imatinib

✍ Janina Bertz; Chuanbing Zang; Hongyu Liu; Marlies Wächter; Kurt Possinger; H. Ph 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 763 KB

Compound 48 (C48) is a novel dual ligand for peroxisome proliferator-activated receptor alpha and gamma (PPAR alpha/gamma). Culture of imatinib-sensitive and -resistant CML cell lines with C48 resulted in a strong growth inhibition which associated with G0/G1 cell cycle arrest. However, it showed no